[HTML][HTML] Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2

G Zhou, Q Zhao - International Journal of Biological Sciences, 2020 - ncbi.nlm.nih.gov
G Zhou, Q Zhao
International Journal of Biological Sciences, 2020ncbi.nlm.nih.gov
A newly identified novel coronavirus (SARS-CoV-2) is causing pneumonia-associated
respiratory syndrome across the world. Epidemiology, genomics, and pathogenesis of the
SARS-CoV-2 show high homology with that of SARS-CoV. Current efforts are focusing on
development of specific antiviral drugs. Therapeutic neutralizing antibodies (NAbs) against
SARS-CoV-2 will be greatly important therapeutic agents for the treatment of coronavirus
disease 2019 (COVID-19). Herein, the host immune responses against SARS-CoV …
Abstract
A newly identified novel coronavirus (SARS-CoV-2) is causing pneumonia-associated respiratory syndrome across the world. Epidemiology, genomics, and pathogenesis of the SARS-CoV-2 show high homology with that of SARS-CoV. Current efforts are focusing on development of specific antiviral drugs. Therapeutic neutralizing antibodies (NAbs) against SARS-CoV-2 will be greatly important therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19). Herein, the host immune responses against SARS-CoV discussed in this review provide implications for developing NAbs and understanding clinical interventions against SARS-CoV-2. Further, we describe the benefits, challenges and considerations of NAbs against SARS-CoV-2. Although many challenges exist, NAbs still offer a therapeutic option to control the current pandemic and the possible re-emergence of the virus in the future, and their development therefore remains a high priority.
ncbi.nlm.nih.gov